Abstract
RVVC affects nearly 138 million women globally each year. Currently there are no FDA approved treatment options. Two Phase 3 studies evaluated the efficacy and safety of Oteseconazole (VT-1161) in the treatment of women with recurrent vulvovaginal candidiasis (RVVC).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
